Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
Northwestern University
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02536794 | https://clinicaltrials.gov/study/NCT01805037 | https://clinicaltrials.gov/study/NCT02988843 | https://clinicaltrials.gov/study/NCT02588651 | https://clinicaltrials.gov/study/NCT03007030 | https://clinicaltrials.gov/study/NCT02388490 | https://clinicaltrials.gov/study/NCT04745949 | https://clinicaltrials.gov/study/NCT04561206 | https://clinicaltrials.gov/study/NCT03409432 | https://clinicaltrials.gov/study/NCT02744612 | https://clinicaltrials.gov/study/NCT03233347 | https://clinicaltrials.gov/study/NCT06377566 | https://clinicaltrials.gov/study/NCT04795869 | https://clinicaltrials.gov/study/NCT01534078 | https://clinicaltrials.gov/study/NCT01771107 | https://clinicaltrials.gov/study/NCT05039073 | https://clinicaltrials.gov/study/NCT05673785 | https://clinicaltrials.gov/study/NCT01492088 | https://clinicaltrials.gov/study/NCT03113500 | https://clinicaltrials.gov/study/NCT01393717 | https://clinicaltrials.gov/study/NCT01780662
Assets
Linked programs
- Anti-B7H1 Monoclonal Antibody MEDI4736: Watchlist Signal (2/5)
- brentuximab vedotin: Registry Stop Signal (5/5)